诊断学理论与实践››2018,Vol. 17››Issue (04): 471-476.doi:10.16150/j.1671-2870.2018.04.024
崔诗爽, 陈生弟, 王刚
收稿日期:2017-11-07出版日期:2018-08-25发布日期:2018-08-25通讯作者:王刚 E-mail: wgneuron@hotmail.com基金资助:
Received:2017-11-07Online:2018-08-25Published:2018-08-25| [1] Parnetti L, Castrioto A, Chiasserini D, et al.Cerebrospinal fluid biomarkers in Parkinson disease[J]. Nat Rev Neurol,2013,9(3):131-140. [2] Wang Y, Shi M, Chung KA, et al. Phosphorylated α-synuclein in Parkinson's disease[J]. Sci Transl Med,2012, 4(121):121ra20. [3] Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al.α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study[J]. Lancet Neurol,2011,10(3):230-240. [4] Malek N, Swallow D, Grosset KA, et al.Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease-a systematic review[J]. Acta Neurol Scand,2014,130(2):59-72. [5] Hong Z, Shi M, Chung KA, et al.DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease[J]. Brain,2010,133(Pt 3):713-726. [6] Ding J, Zhang J, Wang X, et al.Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease[J]. J Neural Transm (Vienna),2017,124(3):353-360. [7] Shi M, Zabetian CP, Hancock AM, et al.Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease[J]. Neurosci Lett,2010,480(1):78-82. [8] Devic I, Hwang H, Edgar JS, et al.Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease[J]. Brain,2011,134(Pt 7):e178. [9] Foulds PG, Mitchell JD, Parker A, et al.Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease[J]. FASEB J,2011,25(12):4127-4137. [10] Shahnawaz M, Tokuda T, Waragai M, et al.Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid[J]. JAMA Neurol,2017,74(2):163-172. [11] Waragai M, Wei J, Fujita M, et al.Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's di-sease[J]. Biochem Biophys Res Commun,2006,345(3):967-972. [12] Kang WY, Yang Q, Jiang XF, et al.Salivary DJ-1 could be an indicator of Parkinson's disease progression[J]. Front Aging Neurosci,2014,6:102. [13] LeWitt P, Schultz L, Auinger P, et al. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease[J]. Brain Res,2011,1408:88-97. [14] Goldstein DS, Holmes C, Sullivan P, et al.Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies[J]. Parkinsonism Relat Disord,2016,31:79-86. [15] Bogdanov M, Matson WR, Wang L, et al.Metabolomic profiling to develop blood biomarkers for Parkinson's di-sease[J]. Brain,2008,131(Pt 2):389-396. [16] Seet RC, Lee CY, Lim EC, et al.Oxidative damage in Parkinson disease: Measurement using accurate biomar-kers[J]. Free Radic Biol Med,2010,48(4):560-566. [17] Sohmiya M, Tanaka M, Tak NW, et al.Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease[J]. J Neurol Sci,2004, 223(2):161-166. [18] Isobe C, Abe T, Terayama Y.Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process[J]. J Neurol,2010,257(3):399-404. [19] Trezzi JP, Galozzi S, Jaeger C, et al.Distinct metabolo-mic signature in cerebrospinal fluid in early parkinson's disease[J]. Mov Disord,2017,32(10):1401-1408. [20] Luan H, Liu LF, Tang Z, et al.Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease[J]. Sci Rep,2015,5:13888. [21] Luan H, Liu LF, Tang Z, et al.Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's di-sease[J]. Parkinsonism Relat Disord,2015,21(11):1371-1372. [22] Brody DM, Litvan I, Warner S, et al.Relationship between uric acid levels and progressive supranuclear palsy[J]. Mov Disord,2016,31(5):663-667. [23] Kasai T, Tokuda T, Ohmichi T, et al.Serum Levels of Coenzyme Q10in Patients with Multiple System Atrophy[J]. PLoS One,2016,11(1):e0147574. [24] Constantinescu R, Rosengren L, Johnels B, et al.Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders[J]. Parkinsonism Relat Disord,2010,16(2):142-145. [25] Hansson O, Janelidze S, Hall S, et al.Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder[J]. Neurology,2017,88(10):930-937. [26] Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies[J]. Ann Clin Transl Neurol,2016,3(10):812-818. [27] Wang Y, Hancock AM, Bradner J, et al.Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy[J]. Am J Pathol,2011,178(4):1509-1516. [28] Shi M, Bradner J, Hancock AM, et al.Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression[J]. Ann Neurol,2011,69(3):570-580. [29] Hall S, Surova Y, Öhrfelt A, et al.CSF biomarkers and clinical progression of Parkinson disease[J]. Neurology,2015,84(1):57-63. [30] Compta Y, Martí MJ, Ibarretxe-Bilbao N, et al.Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease[J]. Mov Disord,2009,24(15):2203-2210. [31] Hall S, Surova Y, Öhrfelt A, et al.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease[J]. Mov Disord,2016,31(6):898-905. [32] Stewart T, Liu C, Ginghina C, et al.Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disea-se progression in the DATATOP cohort[J]. Am J Pathol,2014,184(4):966-975. [33] Majbour NK, Vaikath NN, Eusebi P, et al.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression[J]. Mov Disord,2016,31(10):1535-1542. [34] Zuo LJ, Yu SY, Wang F, et al.Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer[J]. J Clin Neurol,2016,12(2):172-180. [35] Hu Y, Yu SY, Zuo LJ, et al.Parkinson disease with REM sleep behavior disorder: features, α-synuclein, and inflammation[J]. Neurology,2015,84(9):888-894. [36] Cipriani S, Chen X, Schwarzschild MA.Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis[J]. Biomark Med,2010,4(5):701-712. [37] Annanmaki T, Pessala-Driver A, Hokkanen L, et al.Uric acid associates with cognition in Parkinson's disease[J]. Parkinsonism Relat Disord, 2008,14(7):576-578. [38] Moccia M, Picillo M, Erro R, et al.Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease[J]. Eur J Neurol,2015,22(1):93-98. [39] Picillo M, Santangelo G, Moccia M, et al.Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease[J]. J Neural Transm (Vienna),2016, 123(4):371-377. [40] Hirayama M, Nakamura T, Watanabe H, et al.Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease[J]. Parkinsonism Relat Disord,2011,17(1):46-49. [41] Dufek M, Hamanová M, Lokaj J, et al.Serum inflammatory biomarkers in Parkinson's disease[J]. Parkinsonism Relat Disord,2009,15(4):318-320. [42] Eidson LN, Kannarkat GT, Barnum CJ, et al.Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of di-sease severity in subjects with Parkinson's disease[J]. J Neuroinflammation,2017,14(1):164. [43] Rentzos M, Nikolaou C, Andreadou E, et al.Circulating interleukin-15 and RANTES chemokine in Parkinson's disease[J]. Acta Neurol Scand,2007,116(6):374-379. [44] Chen S, Liu Y, Niu Y, et al.Increased abundance of myeloid-derived suppressor cells and Th17 cells in peripheral blood of newly-diagnosed Parkinson's disease patients[J]. Neurosci Lett,2017,648:21-25. [45] Chen Y, Yu M, Liu X, et al.Clinical characteristics and peripheral T cell subsets in Parkinson's disease patients with constipation[J]. Int J Clin Exp Pathol,2015,8(3):2495-504. [46] Wang Y, Liu H, Du XD, et al.Association of low serum BDNF with depression in patients with Parkinson's di-sease[J]. Parkinsonism Relat Disord,2017,41:73-78. [47] Ma J, Jiang Q, Xu J, et al.Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease[J]. Dement Geriatr Cogn Disord,2015, 39(5-6):251-256. [48] Lim NS, Swanson CR, Cherng HR, et al.Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease[J]. Ann Clin Transl Neurol,2016,3(5):346-355. [49] Jiang QW, Wang C, Zhou Y, et al.Plasma epidermal growth factor decreased in the early stage of Parkinson's disease[J]. Aging Dis,2015,6(3):168-173. [50] Parnetti L, Chiasserini D, Bellomo G, et al.Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias[J]. Mov Disord,2011,26(8):1428-1435. [51] Parnetti L, Farotti L, Eusebi P, et al.Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease[J]. Front Aging Neurosci,2014,6:53. [52] Delgado-Alvarado M, Gago B, Gorostidi A, et al.Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study[J]. Mov Disord,2017,32(7):1066-1073. [53] Magdalinou NK, Paterson RW, Schott JM, et al.A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes[J]. J Neurol Neurosurg Psychiatry,2015,86(11):1240-1247. [54] Herbert MK, Eeftens JM, Aerts MB, et al.CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls[J]. Parkinsonism Relat Disord,2014,20(1):112-115. [55] Bäckström DC, Eriksson Domellöf M, Linder J, et al.Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease[J]. JAMA Neurol,2015,72(10):1175-1182. [56] Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al.Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls[J]. Neurology,2017,89(19):1959-1969. [57] Mollenhauer B, Batrla R, El-Agnaf O, et al.A user's guide for α-synuclein biomarker studies in biological flui-ds: Perianalytical considerations[J]. Mov Disord,2017, 32(8):1117-1130. |
| [1] | 武冬冬, 陈玉辉, 刘芳, 刘银红, 蒋景文.脑小血管疾病合并中枢神经系统退行性疾病机制的研究进展[J]. 诊断学理论与实践, 2022, 21(05): 644-649. |
| [2] | 周思锋, 徐海舒, 范欣生.基于不同生物样本代谢组学的OSAHS生物标志物研究进展[J]. 诊断学理论与实践, 2022, 21(04): 535-540. |
| [3] | 陈施吾, 窦荣花, 王玉凯, 王含, 王晓平, 陈先文, 陈玲, 王训, 屈洪党, 陈生弟, Susan Fox, 李燕, 王刚.帕金森病血压管理专家共识[J]. 诊断学理论与实践, 2020, 19(05): 460-468. |
| [4] | 邵丹丹, 付洋, 罗琪, 陈捷, 马建芳, 黄雷.血清尿酸水平与帕金森病发病间关系的前瞻性研究[J]. 诊断学理论与实践, 2020, 19(02): 139-144. |
| [5] | 陈海燕, 杨小宝, 许大康.新生物标志物在胃肠道肿瘤中疗效预测和预后价值的研究进展[J]. 诊断学理论与实践, 2019, 18(06): 704-710. |
| [6] | 罗清琼, 陈福祥.肿瘤免疫治疗策略的转变及相关标志物研究现状[J]. 诊断学理论与实践, 2019, 18(04): 387-393. |
| [7] | 武冬冬, 刘银红, 蒋景文, 陈海波.放射性核素在帕金森病诊断中的应用[J]. 诊断学理论与实践, 2018, 17(06): 726-730. |
| [8] | 杜坤, 杨喜, 卞炳贤, 任懿倩, 张广慧.血清presepsin(sCD14-ST)、降钙素原、C反应蛋白和白介细胞素-6诊断血流细菌感染的诊断性能比较[J]. 诊断学理论与实践, 2018, 17(05): 581-585. |
| [9] | 严振鹏, 杨月嫦, 吴惠涓, 陈坤, 徐云霞.1例多方案评估帕金森病睡眠障碍治疗疗效的病例报告[J]. 诊断学理论与实践, 2018, 17(04): 457-459. |
| [10] | 曹学兵, 曾玮琪, 徐岩.帕金森病冻结步态诊疗研究进展[J]. 诊断学理论与实践, 2018, 17(04): 382-386. |
| [11] | 崔海伦, 张一帆, 管晓军, 黄沛钰, 刘志蓉, 袁园, 刘晓云, 朱红灿, 曹学兵, 陈玲, 陈先文, 陈燕, 商慧芳, 杨任民, 陈生弟, 张敏鸣, 王刚.帕金森病及相关运动障碍的神经影像学诊断专家共识[J]. 诊断学理论与实践, 2018, 17(04): 403-408. |
| [12] | 邹扬, 崔海伦, 胡勇博, 高颖, 张月琪, 陈生弟, 王刚.运动诱发电位用于鉴别诊断原发性帕金森病和多系统萎缩的临床研究[J]. 诊断学理论与实践, 2018, 17(04): 409-413. |
| [13] | 刘春风, 徐兴, 沈赟.多导睡眠监测在帕金森病伴发睡眠障碍诊断中的应用[J]. 诊断学理论与实践, 2018, 17(04): 377-381. |
| [14] | 牟姗, 陈哲君, 谢园园.生物标志物在肾脏损伤诊断中的临床应用[J]. 诊断学理论与实践, 2017, 16(04): 358-362. |
| [15] | 贺娜英, 许洪敏, 黄沛, 陈生弟, 严福华, 凌华威.基于定量磁化率图像观察帕金森病患者黑质体-1退变的研究[J]. 诊断学理论与实践, 2017, 16(02): 147-151. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
